secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001193125-26-006991
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx selects GLP-1 antagonist AMX0318 as development candidate for post-bariatric hypoglycemia
--------------------------------------------------------------------------------

- AMX0318 is a long-acting GLP-1 receptor antagonist for post-bariatric hypoglycemia and other rare diseases.
- Candidate identified through research collaboration with Gubra; Gubra eligible for >$50M in development and commercial milestones.
- Handover of candidate triggers $4M milestone payment to Gubra; mid-single digit royalties on worldwide net sales.
- Amylyx expects to initiate IND-enabling studies and file an IND for AMX0318, though no specific timeline was provided.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000119312526006991/0001193125-26-006991-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000119312526006991/d45370d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-006991

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer